Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis

被引：17

作者：

Dorsey, E. R.

Thompson, J. P.

Noyes, K.

Dick, A. W.

Holloway, R. G.

Schwid, S. R.

机构：

[1] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14620 USA

[2] Univ Rochester, Med Ctr, Dept Community & Prevent Med, Rochester, NY 14620 USA

[3] RAND Corp, Pittsburgh, PA USA

来源：

NEUROLOGY | 2007年 / 68卷 / 18期

关键词：

D O I：

10.1212/01.wnl.0000260699.09720.ad

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality- adjusted life years ( QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small ( loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs ( 12 quality- adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs ( 12 quality- adjusted days).

引用

页码：1524 / 1528

页数：5

共 9 条

[1] Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat [J].

Barratt, A ;

Wyer, PC ;

Hatala, R ;

McGinn, T ;

Dans, AL ;

Keitz, S ;

Moyer, V ;

Guyatt, G .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (04) :353-358

[2]

BROWN MG, 2006, CLIN EFFECTIVENESS D

[3] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[4]

Gold MR, 1996, COST EFFECTIVENESS H

[5] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [J].

Polman, CH ;

O'Connor, PW ;

Havrdova, E ;

Hutchinson, M ;

Kappos, L ;

Miller, DH ;

Phillips, JT ;

Lublin, FD ;

Giovannoni, G ;

Wajgt, A ;

Toal, M ;

Lynn, F ;

Panzara, MA ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :899-910

[6] Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis [J].

Prosser, LA ;

Kuntz, KM ;

Bar-Or, A ;

Weinstein, MC .

VALUE IN HEALTH, 2004, 7 (05) :554-568

[7] Natalizumab plus interferon beta-1a for relapsing multiple sclerosis [J].

Rudick, RA ;

Stuart, WH ;

Calabresi, PA ;

Confavreux, C ;

Galetta, SL ;

Radue, EW ;

Lublin, FD ;

Weinstock-Guttman, B ;

Wynn, DR ;

Lynn, F ;

Panzara, MA ;

Sandrock, AW ;

Fazekas, F ;

Enzinger, C ;

Seifert, T ;

Storch, M ;

Strasser-Fuchs, S ;

Berger, T ;

Dilitz, E ;

Egg, R ;

Deisenhammer, F ;

Decoo, D ;

Lampaert, J ;

Bartholome, E ;

Bier, J ;

Stenager, E ;

Rasmussen, M ;

Binzer, M ;

Shorsh, K ;

Christensen, M ;

Ravnborg, M ;

Sorensen, PS ;

Blinkenberg, M ;

Petersen, B ;

Hansen, HJ ;

Bech, E ;

Petersen, T ;

Kirkegaard, M ;

Eralinna, J ;

Ruutiainen, J ;

Soilu-Hänninen, M ;

Säkö, E ;

Laaksonen, M ;

Reunanen, M ;

Remes, A ;

Keskinarkaus, I ;

Moreau, T ;

Noblet, M ;

Rouaud, O ;

Couvreur, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :911-923

[8] The role of cost-effectiveness analysis in health and medicine [J].

Russell, LB ;

Gold, MR ;

Siegel, JE ;

Daniels, N ;

Weinstein, MC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (14) :1172-1177

[9] Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy [J].

Yousry, TA ;

Major, EO ;

Ryschkewitsch, C ;

Fahle, G ;

Fischer, S ;

Hou, J ;

Curfman, B ;

Miszkiel, K ;

Mueller-Lenke, N ;

Sanchez, E ;

Barkhof, F ;

Radue, EW ;

Jager, HR ;

Clifford, DB .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :924-933

← 1 →